The radiosensitising effects of Iressa (ZD 1839), an epidermal growth factor receptor tyrosine kinase inhibitor, on related bladder cancer cell lines in vitro

被引：0
|
作者：
Maddineni, SB
Sangar, V
Margison, GP
Hendry, JH
Betts, CD
O'Flynn, KJ
Clarke, NW
机构：
来源：
JOURNAL OF UROLOGY | 2003年 / 169卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
520
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [1] The radiosensitizing effects of Iressa (ZD 1839), an epithelial growth factor receptor (EGFR)-tyrosine kinase inhibitor, on related bladder cancer cell lines in vitro
    Maddineni, SB
    Sangar, VK
    Margison, GP
    Hendry, JH
    Betts, CD
    O'Flynn, KJ
    Cowan, RA
    Ramani, VAC
    Clarke, NW
    BJU INTERNATIONAL, 2003, 92 (07) : 836 - 836
  • [2] Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
    Maddineni, SB
    Sangar, VK
    Hendry, JH
    Margison, GP
    Clarke, NW
    BRITISH JOURNAL OF CANCER, 2005, 92 (01) : 125 - 130
  • [3] Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
    S B Maddineni
    V K Sangar
    J H Hendry
    G P Margison
    N W Clarke
    British Journal of Cancer, 2005, 92 : 125 - 130
  • [4] ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation
    Friess, H
    Li, JS
    Buchler, MW
    Korc, M
    Kleeff, J
    GASTROENTEROLOGY, 2004, 126 (04) : A653 - A653
  • [5] ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase
    Hirata, A
    Ogawa, S
    Kometani, T
    Kuwano, T
    Naito, S
    Kuwano, M
    Ono, M
    CANCER RESEARCH, 2002, 62 (09) : 2554 - 2560
  • [6] Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
    Ciardiello, F
    Caputo, R
    Bianco, R
    Damiano, V
    Fentanini, G
    Cuccato, S
    De Placido, S
    Bianco, AR
    Tortora, G
    CLINICAL CANCER RESEARCH, 2001, 7 (05) : 1459 - 1465
  • [7] Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation
    Li, JS
    Kleeff, J
    Giese, N
    Büchler, MW
    Korc, M
    Friess, H
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 25 (01) : 203 - 210
  • [8] Potentiation of radiotherapy by the EGFR tyrosine kinase inhibitor ZD1839 (IRESSA) on bladder cancer in vitro.
    Maddineni, SB
    Sangar, V
    Margison, GP
    Hendry, JH
    O'Flynn, KJ
    Clarke, NW
    BRITISH JOURNAL OF CANCER, 2003, 88 : S62 - S62
  • [9] Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ('Iressa')
    Sewell, JM
    Macleod, KG
    Ritchie, A
    Smyth, JF
    Langdon, SP
    BRITISH JOURNAL OF CANCER, 2002, 86 (03) : 456 - 462
  • [10] Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
    J M Sewell
    K G Macleod
    A Ritchie
    J F Smyth
    S P Langdon
    British Journal of Cancer, 2002, 86 : 456 - 462
12345